HBC Hofseth Biocare

Hofseth Biocare ASA: HBC Ã…rsrapport og ESG rapport 2019

Hofseth Biocare ASA: HBC Årsrapport og ESG rapport 2019

Styret i Hofseth BioCare ASA har i dag 20. mars 2020 godkjent årsrapporten for 2019.

Årsrapporten inkludert ESG-rapport (kapittel 5) for 2019 ligger vedlagt.

For ytterligere informasjon, vennligst kontakt:

James Berger, Head of Investor Relations & Strategy i Hofseth BioCare ASA

Mob:

E-post:

Jon Olav Ødegård, CFO i Hofseth BioCare ASA

Mob:

E-post:

Om Hofseth BioCare ASA:

HBC er et norsk bioteknologiselskap som utvikler høyverdige ingredienser og ferdigprodukter av avskjær fra norsk laks. Ingredienser videreutvikles til forskning og prekliniske studier i flere klinikker og forskningslaboratorier på universiteter i flere land. Ledende kliniske og prekliniske kandidater utvikles mot gastrointestinal beskyttende medisinsk mat, medisinsk mat for å hjelpe til med å behandle aldersrelatert sarkopeni og fremtidige kliniske studier for behandling av anemi og NEC-IBS med fraksjoner fra hydrolysert lakseprotein. Selskapet er basert på kjerneverdiene bærekraft, sporbarhet og optimal utnyttelse av naturressurser. Gjennom en innovativ hydrolyseteknologi kan HBC bevare kvaliteten på lipider, proteiner og kalsium fra fersk lakseavskjær.

Hofseth BioCares hovedkontor er lokalisert i Ålesund med avdelinger i Oslo, Chicago, Mumbai, Menlo Park og Tokyo. HBC er notert på Axess-listen på Oslo Børs med ticker "HBC". Mer informasjon om Hofseth BioCare på

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

Vedlegg

EN
20/03/2020

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT

Hofseth BioCare ASA: FOURTH QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up from NOK 64.9 million in Q4 2024. Full year 2025, total operating revenues amounted to NOK 256.3 million (265.5). Total operating revenue in 2024 included NOK 8.1 million of gain on sale of assets. EBITDA for the quarter was negative NOK 26.5 million, compared to negative NOK 26.1 million in Q4 2024. For full year 2025, EBITDA was negative...

February 13, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Notification of major shareholdings

Notification of major shareholdings Effective February 9, 2026, the “Bonafide Investment Fund – Best Catches I” made a subscription in kind to the “Bonafide Investment Fund – HBC II”. Following the subscription in kind, the Bonafide Investment Fund – Best Catches I no longer holds shares in Hofseth Biocare ASA. According to the information published on the website of the Oslo Stock Exchange, the total number of outstanding shares of Hofseth Biocare ASA currently amounts to 395,081,030. Based on this figure, IFM Independent Fund Management AG will hold a total of 16.62% of the voting rights...

February 11, 2026 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on c...

Hofseth BioCare ASA: Cancellation of Subsequent Offering – Update on completion of Private Placement NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 throug...

December 15, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION

Hofseth BioCare ASA: PRIMARY INSIDER NOTIFICATION Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has subscribed for 368,320 Offer shares in the Subsequent Offering and Mr. Baldegger will hold 3,616,296 shares in HBC after the share capital is registered, equal to approximately 0.92 % of the total outstanding A-shares with voting rights.  For further information, contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: E-mail: This information is subject to the disclosure requirements in the Market Abuse Regulation EU 596/20...

November 21, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING

Hofseth BioCare ASA: RESULTS OF SUBSEQUENT OFFERING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to previous announcements by Hofseth BioCare ASA (the "Company") regarding a subsequent offering with gross proceeds of up to approx. NOK 30,000,000 through issuance of up to 16,666,666 new ordinary share...

November 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch